PR88055

HYDERABAD, India, 11 February 2021 /PRNewswire=KYODO JBN/ --

    Sai Life Sciences, one of India's fastest growing Contract Research,

Development & Manufacturing Organizations [

https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=dr-mahavir-prashad]

(CRDMOs), today announced the addition of Dr. Mahavir Prashad, an acknowledged

scientific leader and industry veteran, to its scientific leadership team as

Vice President of Early Phase Process Development. With over three decades of

experience in advanced research, and roles of increasing responsibility in one

of the world's leading pharmaceutical companies, Dr. Prashad will provide

impetus to Sai Life Sciences' growing capabilities and help accelerate the drug

development programmes of its customers.

    Making the announcement, CEO & Managing Director of Sai Life Sciences,

Krishna Kanumuri said, "We see Early Phase Process Development as a key pivot

in compressing the time to market of our clients' drug development programs.

This priority has now received significant momentum with the joining of Dr.

Mahavir Prashad. His deep scientific expertise and rich experience of managing

outsourced drug development programs will no doubt be a valuable addition as we

strive to build a world class delivery engine."

    Dr. Prashad is a recognized leader in chemical process R&D and leveraging

green chemistry principles and modern technologies in API synthesis. He

possesses an excellent scientific track record through 94 publications, 4

review articles, 1 book chapter, 71 patent/applications, and 10 invited

lectures at scientific conferences. He was awarded Novartis Leading Scientist

award in 2002 and also the 2010 Diversity & Inclusion award of the Novartis

Pharmaceuticals Corporation. Dr. Prashad has a Ph.D. in Organic Chemistry from

the Central Drug Research Institute in Lucknow, India and was awarded a

Post-Doctoral Research Fellowship at Duke University in North Carolina, USA.

    Commenting on his appointment, Dr. Mahavir Prashad said, "I am very excited

to be joining Sai Life Sciences and its passionate leadership team with a clear

Early Phase Development acceleration strategy. I am looking forward to working

with talented and dedicated scientists at Sai who are enabling their partners

in delivering novel medicines to patients in a speedy and socially responsible

manner through science and innovation."

    Sai Life Sciences is currently amid an organization-wide transformation. It

is investing US$150 million during 2019-23, as part of the Sai Nxt initiative,

across three core areas – people & culture, processes & automation,

infrastructure & scientific capabilities.

    About Sai Life Sciences

    Sai Life Sciences is a full-service CRO/ CDMO

[https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=dr-mahavir-p

rashad] driven by a vision to support the launch of 25 new medicines by 2025.  

It works with innovator pharma and biotech companies globally, accelerating the

discovery, development, and manufacture of complex small molecules. As a

pure-play CRO-CDMO, Sai Life Sciences has served diverse NCE development

programs, consistently delivering value based on its quality and

responsiveness. Today, it works with 7 of the top 10 large pharma companies, as

well as several small and mid-sized pharma & biotech companies. Sai Life

Sciences is privately held and backed by global investors, TPG Capital and HBM

Healthcare Investments. www.sailife.com

[https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=dr-mahavir-p

rashad]

    Photo:

https://mma.prnewswire.com/media/1437298/Mahavir_Prashad_Sai_Life_Sciences.jpg

    Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

    Source: Sai Life Sciences